Abstract:
본 발명은 불포화 지방산의 층상형 금속 수산화물과의 혼성체에 관한 것으로, 보다 구체적으로는 불포화 지방산의 안정성을 증가시키면서 다양한 용매 및 제형에서 분산성이 뛰어나 제제화가 용이한 불포화 지방산의 층상형 금속 수산화물과의 혼성체, 그 제조방법, 및 그 혼성체를 포함하는 피부 외용제 및 기능성 식품에 관한 것이다. 불포화 지방산, 필수 지방산, 층상형 금속 수산화물, 혼성체
Abstract:
A mixture material in which a complex of an active ingredient-micelle is hybridized into pores of a meso porous inorganic structure is provided to make a drug be stable at light and heat and show the controlled releasing property, thereby lowering the toxicity of the drug itself and also increasing the transmission efficiency of the drug into cells. A method for preparing the same is provided to simply obtain the mixture material with only two steps. A mixture material is characterized in that a complex of an active ingredient-micelle in which the active ingredient is supported on a micelle of a biocompatible copolymeric polymer surfactant is hybridized with pores of a meso porous inorganic structure, wherein the surfactant is a compound of EOnPOmEOn (n is an integer from 20-106 and m is an integer from 40-100), the meso porous inorganic structure is made of SiO2 or TiO2, and the active ingredient is a water-insoluble drug. A method for preparing the mixture material comprises the steps of: (a) reacting an aqueous solution of a mixture consisting of an active ingredient, a biocompatible copolymeric polymer surfactant with the concentration of more than the critical micelle formation, and an inorganic precursor at a temperature of 25-40 deg.C to form a complex of an active ingredient-micelle in which the active ingredient is supported on the micelle of the surfactant; and (b) subjecting the complex formed aqueous solution to hydrothermal reaction at a temperature of 80-130 deg.C to prepare an organic-inorganic complex.
Abstract:
An injectable drug carrier comprising double-layered hydroxide is provided to remove a destruction risk of blood vessel by the double-layered hydroxide, and deliver an effective drug into the human body without toxicity and side effects. The injectable drug carrier comprises the nontoxic double-layered hydroxide and a pharmaceutically acceptable additive, wherein the particle size of the double layered hydroxide is 100-300 nm; and drug is MTX(methotrexate). The method for preparing the injectable drug carrier comprises the steps of: titrating divalent or trivalent metal salt solution with base solution to synthesize the double-layered hydroxide by hydro thermal method or at room temperature; and regulating the particle size of the synthesized double-layered hydroxide, wherein the divalent metal is magnesium, calcium or zinc, and the trivalent metal is aluminum or iron; and the base solution is sodium hydroxide or ammonia.
Abstract:
PURPOSE: A hybrid of amlodipine with layered silicate and a preparation process thereof are provided, which hybrid is easily dispersed in aqueous solution to increase bioavailability of amlodipine, and is non-hygroscopic enabling easy manufacturing of formulation. CONSTITUTION: The hybrid of amlodipine with layered silicate is provided, wherein the amlodipine is inserted between layers of silicate; the layered silicate is selected from montmorillonite, beidellite, nontronite, hectorite, saponite, illite, celadonite, gluconite, clay and bentonite; inorganic salt or organic base is added into the hybride in order to regulate release of amlodipine; the organic base is aminoalkyl metacrylate copolymer or polyvinylacetal diethylaminoacetate; and the inorganic salt is selected from calcium salt, sodium salt, potassium salt and ammonium salt. The process for preparing the hybrid of amlodipine with layered silicate comprises the steps of: (1) dispersing the layered silicate in aqueous solution; (2) dissolving amlodipine in ethanol or water; and (3) mixing the layered silicate solution with the amlodipine solution and stirring them.
Abstract:
PURPOSE: Provided are vitamin-inorganic hybrid which has excellent stability to heat, light and oxygen and excellent dispersibility, and sustainedly releases vitamin to maintain efficacies of vitamin for a ling time, and a preparation thereof. CONSTITUTION: The vitamin-inorganic hybrid complex is characterized by inserting vitamin or its derivative between layers of layered double metal hydroxide as an inorganic carrier by ion exchange reaction. It is represented by the formula:(M¬2+ 1-x N¬3+ x (OH)2)(A¬n-)x/n yH2O.
Abstract translation:用途:提供一种维生素 - 无机杂化剂,其对热,光和氧具有优异的稳定性和优异的分散性,并持续释放维生素以维持维生素的疗效,并提供一种制剂。 组成:维生素 - 无机杂化复合物的特征在于通过离子交换反应将维生素或其衍生物插入层状双金属氢氧化物层之间作为无机载体。 它由下式表示:(M 2+ 2+ 1-x N 3+ x(OH)2)(A n - n - )x / n y H 2 O.
Abstract:
PURPOSE: A process of preparing a hybrid material containing 3-benzoyl-α -methylbenzene acetic acid, 4-biphenyl acetic acid, minocycline, etc. is provided. Whereby, the new hybrid material is useful in stabilization and delivery of specified drugs, low in adverse effects and excellent in stability and can be used in the form of an ointment, patch, oral administration, injection or the like. CONSTITUTION: The hybrid material is prepared by coprecipitation or ion exchange reaction of: a drug selected from the group consisting of 3-benzoyl-α-methylbenzene acetic acid, 4-biphenyl acetic acid and minocycline; and a layered inorganic material selected from the group consisting of layered silicate, layered aluminosilicate, layered phosphate and layered metal oxide.
Abstract:
PURPOSE: A preparation method of porous crosslinked clay is provided which is characterized in that nano-sol particles of cationic-surface reformed metallic oxide instead of cationic cluster compounds of metallic oxide in conventional method are used for ion-exchanging inorganic cations between layers of clay and crosslinking. Accordingly, the resultant crosslinked clay has much improved surface area and thermal stability. CONSTITUTION: The method comprises the steps of: preparing nano-sol particles of metallic oxide such as SiO2 or Fe2O3-SiO2; reforming the surface of particles by cationic complexing metal, Fe; ion exchanging and crosslinking by adding prepared nano-sol solution to a suspension of clay, as montmorillonite or smectite-based clay; centrifuging, washing with aid and freeze-drying crosslinked clay; calcining at 400-550deg.C. The organic surfactant or NH4F is added to improve porous characteristics in preparation of crosslinked clay which has 300-1000m2/g of surface area, 1-3nm of pore size and 500-800deg.C of thermal stability.
Abstract:
PURPOSE: The aim is to provide a bio-inorganic hybrid complex which can carry genetic materials between layers of metal layered double hydroxide by anion exchange reaction. CONSTITUTION: The invention provides the complex of formula I (M2+1-xN3+x(OH)2)(An-)x/n·yH2O, wherein M represents metal cation such as Mg¬2+, Ni¬2+, Cu¬2+ and Zn¬2+ which are alkali-earth metals or transition metals having a valence of two. N represents metal cation such as Al¬3+, Cr¬3+, Fe¬3+, V¬3+ and Ga¬3+ which are transition metal having valence of three. A represents anionic bio-compounds such NO3¬-, CO3¬2-, Cl¬-, SO4¬2-, meta late and organic acid having a valence of n. 0 0. Charge of the layer can be controlled by changing the ratio of the metal according to X. This complex is non-toxic, reversibly dissociated and stable.
Abstract:
본 발명은 강력한 유전자 치료제인 siRNA (small interfering RNA)와 표적지향성 층상형 무기 수산화물과의 나노혼성체, 그 제조방법, 및 표적지향성 siRNA-층상형 무기 수산화물 나노혼성체를 함유하는 종양 치료용 약학 조성물에 관한 것이다. 본 발명에 따른 나노혼성체는, 종양 마커와 특이적으로 결합할 수 있는 표적지향성 다작용기 리간드가 결합된 층상형 무기 수산화물과 나노혼성체를 이루고 있는 siRNA의 생체 내 안정성이 종양특이적 전달 효율을 향상시켜 비교적 낮은 농도의 투여량에서 siRNA의 종양치료 활성을 나타내므로 범용적인 표적지향성 종양치료에 널리 활용될 수 있을 것이다. siRNA, 층상형 무기 수산화물, 표적지향성, 나노하이브리드, 유전자 치료제